Clinical Trial Update: JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis [Phase 2]

View source ↗

Summary

Phase 2 trial update of ruxolitinib in myelofibrosis completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: French Innovative Leukemia Organisation | Conditions: Myelofibrosis | Phase 2 | Status: COMPLETED